Philip Rancitelli, MD
Allergy & Immunology · Columbus, OHNPI 1942270111
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.0%), speaking fees and education — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by GSK at 50.3% of the total. Reporting peaked in 2020 at $2,828 and has fallen 76.2% since, to $674 in 2025.
Across 191 payments — averaging $29.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- Sanofi$849
- AstraZeneca$343
- Regeneron Healthcare Solutions, Inc.$210
- Novartis$200
- Genentech USA, Inc.$183
- plus $1K from 20 others
What the payments were for
- Speaking & faculty fees$2,40042%
- Food & beverage$3,23957%
- Education$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 29 | $2,855 |
| Sanofi | 58 | $849 |
| AstraZeneca | 17 | $343 |
| Regeneron Healthcare Solutions, Inc. | 11 | $210 |
| Novartis | 9 | $200 |
| Genentech USA, Inc. | 9 | $183 |
| Optinose US, Inc. | 9 | $166 |
| Alk-abello, Inc | 5 | $101 |
| Pfizer | 4 | $78 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $69 |
| CSL Behring | 4 | $65 |
| Kaleo, Inc. | 4 | $64 |
| Covis Pharma GmbH | 4 | $62 |
| Hikma Pharmaceuticals USA | 3 | $61 |
| Amgen | 4 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Eyevance Pharmaceuticals LLC | 3 | $40 |
| Cycle Pharmaceuticals Inc | 1 | $36 |
| Grifols USA, LLC | 2 | $31 |
| Lilly USA, LLC | 1 | $30 |
| Biocryst US Sales Co., LLC | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| AbbVie | 1 | $23 |
| Blueprint Medicines Corporation | 1 | $23 |
| Merck | 1 | $14 |
| Hologic Sales And Service, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$2,400
- DUPIXENT$104
How this compares
$5,678 in reported general payments places this provider in the 65th percentile of 128 allergy & immunology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 51 | $217,334 |
| XolairOmalizumab | 20 | $69,248 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $15,185 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $14,328 |
| Arnuity ElliptaFluticasone Furoate | 34 | $9,642 |
| Epinephrine | 33 | $5,603 |
| Azelastine Hcl | 177 | $4,688 |
| Ipratropium Bromide | 111 | $3,510 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,858 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $1,365 |
| Montelukast Sodium | 176 | $1,185 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $1,126 |
| Olopatadine Hcl | 13 | $1,032 |
| Fluticasone Propionate | 88 | $894 |
| Mometasone Furoate | 17 | $850 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $2,855 | $39,15581 claims |
| Hikma Pharmaceuticals USAEpinephrine | $61 | $5,60333 claims |
| AstraZenecaSymbicort | $343 | $2,85812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 128 allergy & immunology providers in Ohio.
Other allergy & immunology in Columbus
- Donald McNeilColumbus$136K
- Scott BagenstoseColumbus$23K
- Monica KraftColumbus$9K
- Bryan MartinColumbus$7K
- Grace RyuColumbus$5K
- Debora Ortega-CarrColumbus$4K
- Charity FoxColumbus$4K
- Rekha RaveendranColumbus$4K
- Justin GreiweCincinnati$1M
- Jonathan BernsteinCincinnati$810K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.